Opioids

Created

2021-09-08

Last Modified

Files

1 Download↓
rx_2021_09_Opioids_V1.csv (5.75 MB)
↓

Tags




Abstract

Concept set intended to identify patients with an exposure to opioids.

Affiliation(s)

Children's Hospital of Philadelphia

Funder(s)

Provenance

This concept set was first used as part of the Outcomes of Children with Kidney Stones: Retrospective Cohort Study. The concept set was then re-used in 2024 for Impact of the 2014 NHLBI Guidelines on Cerebrovascular Events in Sickle Cell Disease to identify sickle cell patients with hospitalizations for pain.

Description

This medication concept set includes the following opioids: tilidine, tramadol, buprenorphine, butorphanol, dezocine, codeine, fentanyl, dihydrocodeine, morphine, hydromorphone, Ketobemidone, meperidine, methadone, nalbuphine, opium, oxycodone, papaveretum, pentazocine, pirinitramide, propoxyphene, or tapentadol.

The concept set was re-used from prior work in a PKIDS study for work investigating sickle cell disease. The code set is a part of a clinical variable definition for inpatient hospitalization. To be classified with pain hospitalization, a patient needs to have a tleast one occurrence of diagnosis code in the inpatient visit OR two exposures to opioids on separate days. Face validity was checked using manual review on a small subset of patient. 100% specificity and sensitivities were seen.

Development Code

https://atlassian.chop.edu/bitbucket/projects/PRP/repos/pkids_stone/browse

Vocabulary

RxNorm , RxNorm Extension

Clinical Subjects Headings

Opioid Agonist
Receptor Agonist
Nervous System Agent

Related Resource

Related Phenotype

Related Person

Related Study

Thumbnail Image
Pediatric KIDney Stone (PKIDS) Care Improvement Network
Children's Hospital of Philadelphia
Study to improve the ability of pediatric patients and their caregivers to select surgical treatment options for kidney stones and to enable urologists to use techniques that result in the best outcomes for these surgeries.
Thumbnail Image
Impact of Early and Universal Hydroxyurea on Cerebrovascular Outcomes in Sickle Cell Disease
Children's Hospital of Philadelphia
Study to identify the impact of the 2014 NHBLI guidelines recommending early and universal hydroxyurea (HU) on HU prescriptions and cerebrovascular outcomes in a national cohort of children and young adults born between 2009-2023, and to determine the relationship between timely HU initiation before 2 years of age and the occurence of cerebrovascular disease in children and young adults with sickle cell disease.

Related Concept Set

Related Publications

Creative Commons license

a CC-BY Attribution 4.0 License.
Except where otherwised noted, this item's license is described as a CC-BY Attribution 4.0 License.